logo

Chinook Therapeutics, Inc. (KDNY)



Trade KDNY now with
  Date
  Headline
10/2/2020 11:19:57 AM Stock Alert: Aduro Biotech Up 8%
6/2/2020 7:37:33 AM Aduro To Acquire All Outstanding Capital Stock Of Chinook
9/4/2019 8:35:24 AM Aduro Biotech Announces First Patient Dosed In Phase 2 Study Of ADU-S100 With KEYTRUDA
6/2/2019 1:01:25 PM Aduro Biotech And Novartis Present Results From Ongoing Phase 1b Study Of ADU-S100 With PDR001
4/22/2019 8:40:33 AM Aduro Biotech Appoints Dimitry Nuyten As Chief Medical Officer
1/5/2018 8:03:24 AM Aduro Biotech Says Promotes Jennifer Lew To CFO
11/10/2017 8:12:54 AM Aduro Biotech Announces Data From Preclinical Studies With ADU-1604, Anti-CTLA-4 Monoclonal Antibody
9/27/2017 8:10:36 AM Aduro Biotech Says First Patient Dosed In Phase 1 Clinical Trial Of Personalized Immunotherapy PLADD
9/26/2017 8:05:25 AM Aduro Biotech Says First Patient Dosed In Phase 1b Dose Escalation And Dose Expansion Clinical Trial On ADU-S100
6/1/2017 8:12:36 AM Aduro Biotech Gets FDA Clearance Of IND To Evaluate Combination Of ADU-S100 With PDR001 For Solid Tumors And Lymphomas
1/19/2017 8:12:44 AM Aduro Biotech Enters Into License Agreement For Proprietary Neoantigen Identification Technology